This study is exploring a new treatment plan for people living with HIV-1 who have the virus under control. It will compare a weekly pill containing islatravir and lenacapavir (ISL/LEN), with the usual daily treatment, which includes 2 or 3 antiretroviral agents (ARVs). Participants should have HIV-1 RNA levels below 50 copies/mL for at least 6 months before joining. The main goal is to see if the new treatment works as well as the current one after 48 weeks.

Eligibility requirements include having consistently low HIV-1 levels and being on a stable treatment plan. You can’t join if you’ve had previous treatment failures, have active infections like tuberculosis or hepatitis B, or if you’ve used ISL or LEN before. Females of childbearing age should use approved birth control methods.

• Study involves switching to a weekly pill, comparing it to daily treatment.
• Lasts for 48 weeks, with follow-up visits required.
• Participants must have stable HIV-1 levels and no serious infections.